Patients with advanced, radioiodine-refractory, differentiated thyroid cancer demonstrated encouraging response rates and PFS when treated with lenvatinib, according to data from a phase 2 trial.Lenvatinib (Lenvima, Eisai) — a multi-targeted tyrosine kinase inhibitor that targets VEGF receptors 1-3 and fibroblast growth factor receptors 1-4 —induced responses in patients who had and had not previously received VEGF therapy, results showed.
No comments:
Post a Comment